Compositions and methods for treating acute radiation syndrome
AssigneeBioincept, LLC
InventorEytan R. Barnea
Life of this patent
Estimating the term…
Abstract
Embodiments are directed to a method of treating acute radiation syndrome comprising administering to a subject following exposure to radiation a PIF peptide. Some embodiments describe a method of treating acute radiation syndrome following radiation exposure comprising transplanting bone marrow that has been exposed to a PIF peptide prior to transplantation into a subject. Other embodiments describe a method of increasing engraftment of a transplanted organ, tissue, or cell by pre-exposing the organ, tissue, or cell to a PIF peptide.
Claims39
A method of treating and/or preventing acute radiation syndrome in a subject in need thereof following exposure to radiation comprising administering to the subject a therapeutically effective amount of a PIF peptide, mimetics thereof, pharmaceutically acceptable salts thereof, or combinations thereof.
-40. (canceled)
A method of treating and/or preventing acute radiation syndrome following radiation exposure comprising transplanting one or a plurality of bone marrow cells into a subject in need thereof, wherein the one or plurality of bone marrow cells is pre-exposed to a therapeutically effective amount of PIF peptide prior to transplantation, and the PIF peptide comprises or consists of an amino acid sequence having at least 86% sequence homology to an amino acid sequence selected from:
- SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, SEQ ID NO:
- 12, SEQ ID NO:
- 13, SEQ ID NO:
- 14, SEQ ID NO:
- 15, SEQ ID NO:
- 16, SEQ ID NO:
- 17, SEQ ID NO:
- 18, SEQ ID NO:
- 19, SEQ ID NO:
- 20, SEQ ID NO:
- 21, SEQ ID NO:
- 22, SEQ ID NO:
- 23, SEQ ID NO:
- 24, SEQ ID NO:
- 25, SEQ ID NO:
- 26, SEQ ID NO:
- 27, SEQ ID NO:
- 28, SEQ ID NO:
- 29, mimetics thereof, and pharmaceutically acceptable salts thereof, and combinations thereof.
-44. (canceled)
-49. (canceled)
A method of treating and/or preventing adult or juvenile type I or type II diabetes comprising transplanting one or a plurality of pancreatic islet cells into a subject in need thereof, wherein the islet cells are pre-exposed to a therapeutically effective amount of PIF peptide prior to transplantation, and wherein the PIF peptide comprises or consists of an amino acid sequence having at least 86% sequence homology with:
- SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, SEQ ID NO:
- 12, SEQ ID NO:
- 13, SEQ ID NO:
- 14, SEQ ID NO:
- 15, SEQ ID NO:
- 16, SEQ ID NO:
- 17, SEQ ID NO:
- 18, SEQ ID NO:
- 19, SEQ ID NO:
- 20, SEQ ID NO:
- 21, SEQ ID NO:
- 22, SEQ ID NO:
- 23, SEQ ID NO:
- 24, SEQ ID NO:
- 25, SEQ ID NO:
- 26, SEQ ID NO:
- 27, SEQ ID NO:
- 28, SEQ ID NO:
- 29, mimetics thereof, pharmaceutically acceptable salts thereof, or combinations thereof.
(canceled)
(canceled)
(canceled)
A method of increasing the likelihood of successful engraftment of a transplanted organ, tissue, or cells comprising transplanting an organ, tissue, or cell into a subject in need thereof, wherein the organ, tissue, or cell is exposed to a PIF peptide prior to transplantation, wherein the PIF peptide comprises or consists of an amino acid sequence having at least 86% sequence homology to an amino acid sequence chosen from:
- SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, SEQ ID NO:
- 12, SEQ ID NO:
- 13, SEQ ID NO:
- 14, SEQ ID NO:
- 15, SEQ ID NO:
- 16, SEQ ID NO:
- 17, SEQ ID NO:
- 18, SEQ ID NO:
- 19, SEQ ID NO:
- 20, SEQ ID NO:
- 21, SEQ ID NO:
- 22, SEQ ID NO:
- 23, SEQ ID NO:
- 24, SEQ ID NO:
- 25, SEQ ID NO:
- 26, SEQ ID NO:
- 27, SEQ ID NO:
- 28, SEQ ID NO:
- 29, mimetics thereof, and pharmaceutically acceptable salts thereof, and combinations thereof.
-63. (canceled)
-66. (canceled)
(canceled)
A method of increasing the viability of an organ, tissue, or cell prior to its transplantation into a subject in need of transplantation comprising treating the organ, tissue or cell with a therapeutically effective amount of PIF peptide prior to transplantation, wherein the PIF peptide comprises or consists of an amino acid sequence having at least 86% sequence homology to an amino acid sequence chosen from:
- SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, SEQ ID NO:
- 12, SEQ ID NO:
- 13, SEQ ID NO:
- 14, SEQ ID NO:
- 15, SEQ ID NO:
- 16, SEQ ID NO:
- 17, SEQ ID NO:
- 18, SEQ ID NO:
- 19, SEQ ID NO:
- 20, SEQ ID NO:
- 21, SEQ ID NO:
- 22, SEQ ID NO:
- 23, SEQ ID NO:
- 24, SEQ ID NO:
- 25, SEQ ID NO:
- 26, SEQ ID NO:
- 27, SEQ ID NO:
- 28, SEQ ID NO:
- 29, mimetics thereof, and pharmaceutically acceptable salts thereof, and combinations thereof.
A method of increasing the likelihood of acceptance of a transplant of a donor organ, tissue, or cell into a subject, the method comprising exposing the organ, tissue or cell to one or more compositions comprising at least one PIF peptide or a mutant thereof or a pharmaceutically acceptable salt thereof prior to transplanting the organ, tissue, or cell into the subject.
-98. (canceled)
Dependencies are inferred from the claim text.